Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
-
-
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
-
Novavax filed for Emergency Use of COVID-19 vaccine in the United Arab Emirates
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
-
Novavax filed for interim authorization of COVID-19 vaccine in singapore
On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of…
-
Imported Monkeypox case reported in Maryland
On Nov. 17, 2021, scientists at the Centers for Disease Control and Prevention (CDC) announced they were collaborating…
-
Novavax and Serum Institute of India received Emergency Use Authorization for COVID-19 vaccine in the Philippines
On Nov. 17, 2021, Novavax and and Serum Institute of India announced that the Philippine Food and Drug…
-
Novavax confirmed European Medicines Agencyreview of COVID-19 vaccine filing for Conditional Marketing Authorization
On Nov. 17, 2021, Novavax announced that the European Medicines Agency (EMA) had begun its evaluation of an…
-
Zosano Pharma announced successful formulation of COVID-19 vaccine candidate on its microneedle patch system
On Nov. 17, 2021, Zosano Pharma announced that the Philippine Food and Drug Administration had granted emergency use…
-
Novavax announced submission of Biologics License Application in South Korea for approval of NVX-CoV2373
On Nov. 15, 2021, Novavax and SK bioscience announced submission of a Biologics License Application (BLA) for Novavax’…
-
Long-term study of children with COVID-19 began
On Nov. 15, 2021, a large, long-term study of the impacts of COVID-19 on children announced it had…
-
COVID-19 | Nanotechnology | Vaccine | WHO
Novavax filed COVID-19 vaccine for Emergency Use listing with World Health Organization
On Nov. 4, 2021, Novavax announced the completion of its rolling submission to the World Health Organization (WHO)…
-
Novavax filed COVID-19 vaccine for provisional approval in New Zealand
On Nov. 3, 2021, Novavax announced the company had filed for provisional approval of the vaccine to the…
-
Novavax filed for COVID-19 vaccine authorization with Health Canada and completed submission to EMA
On Nov. 1, 2021, Novavax announced the completion of its rolling submission to Health Canada for authorization of…
-
Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia
On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…
-
Novavax filed for provisional approval of its COVID-19 vaccine in Australia
On Oct. 29, 2021, Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA)…
-
Novavax filed for authorization of its COVID-19 vaccine in the United Kingdom
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
-
Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…
-
Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
-
Novavax included in University of Oxford Com-COV3 study comparing mixed COVID-19 vaccine in adolescents
On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing…
-
Novavax initiated phase 1/2 clinical trial of combination vaccine for COVID-19 and seasonal influenza
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
-
Takeda announced manufacture and provision of 150 million doses of Novavax COVID-19 vaccine candidate to the government of Japan
On Sept. 7, 2021, Takeda Pharmaceutical announced the Government of Japan’s Ministry of Health, Labour and Welfare purchase…
-
Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…
-
Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…
-
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
-
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
-
Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
-
Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine
On Jun. 11, 2021, Novavax announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine…
-
NIH launched clinical trial of universal influenza vaccine candidate
On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…
-
Novavax announced MOU to explore expansion of COVID-19 vaccine activities in South Korea
On May 22, 2021, Novavax announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry…
-
Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
